ClinicalTrials.gg
RecruitingNCT03358693MSIDUpdated Jul 22, 2025

Molecular Signatures in Inflammatory Skin Disease

An observational study in Atopic Dermatitis and Psoriasis, sponsored by Prof. Dr. Stephan Weidinger. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Prof. Dr. Stephan Weidinger · Observational

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Dermatitis, Atopic with a site in Germany — 19 open to participants now, 42 under way, 9 of them phase 3. Dermatitis, Atopic · Germany.

Planned enrollment
14th of 21
300 · median 634
Started
2017
with 10 others
Observational
21 of 230
9 open now
Primary completion
2028-12
later than 32 of 41 live
Registered
90th of 230
by date

Among the 230 studies in Dermatitis, Atopic with a site in Germany, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 11 that started in 2017, is one of 21 observational ones, reaches primary completion later than 32 of the 41 other live ones, and was the 90th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

19 of the 230 studies in Dermatitis, Atopic with a site in Germany are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Dermatitis, Atopic with a site in Germany, or all of them as a file.
02

Study summary

This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.

Read the detailed description

This is an exploratory study with the aim to identify molecular profiles and signatures in skin and blood that correlate with inflammatory skin disease, disease activity and disease progression, and that are associated with possible disease subtypes/endotypes. Primary target variables are differentially expressed genes (alone or in combination), secondary target variables are genetic, immunological and microbiological signatures. Influencing variables of interest include age of manifestation, disease duration, disease activity/severity, disease progression, comorbidities and therapy/treatment. Obtained biomaterial will be used for molecular profiling including DNA/RNA sequencing, ELISA, mass spectrometry, flow cytometry to identify markers and/or signatures that can correlate with individual disease courses.

03

Conditions studied

  • Atopic Dermatitis
  • Psoriasis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic inflammatory skin disease who receive systemic therapy from their treating dermatologist during routine care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written and comply with the protocol
  • Dermatologist-diagnosed chronic inflammatory skin disease
  • Subject receives systemic therapy within routine care (in-label use of biologics)

Exclusion criteria

Exclusion Criteria:

  • Subject is unable to provide written or comply with the protocol.
  • Having used /immunomodulating therapy or phototherapy within 4 weeks before the baseline visit.
  • Treatment of selected skin areas to be examined with topical or topical calcineurin inhibitor within 1 week before the baseline visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Psoriasis patients receiving Tumor Necrosis Factor (TNF) Inhibitors

    Pso\_Tumor Necrosis Factor (TNF) Inhibitors

    Drug: Anti-TNF

  • Psoriasis patients receiving Interleukin (IL)-12/23 Inhibitors

    Interleukin (IL)-12/23 Inhibitors

    Drug: Anti-IL12/23

  • Psoriasis patients receiving Interleukin (IL)-17 Inhibitors

    Pso\_Interleukin (IL)-17 Inhibitors

    Drug: Anti-IL17

  • Atopic dermatitis patients receiving dupilumab

    Dupilumab

    Drug: Dupilumab

  • Atopic dermatitis patients receiving lebrikizumab

    Brodalumab

    Drug: Lebrikizumab

  • Atopic dermatitis patients receiving tralokinumab

    Tralokinumab

    Drug: Tralokinumab

  • Atopic dermatitis patients receiving baricitinib

    Baricitinib

    Drug: Baricitinib

  • Atopic dermatitis patients receiving abrocitinib

    Abrocitinib

    Drug: Abrocitinib

  • Atopic dermatitis patients receiving upadacitinib

    Upadacitinib

    Drug: Upadacitinib

  • Psoriasis patients receiving Interleukin (IL)-23 Inhibitors

    Interleukin (IL)-23 Inhibitors

    Drug: Anti-IL23

  • Atopic dermatitis patients receiving Interleukin (IL)-31 Inhibitors

    Interleukin (IL)-31 Inhibitors

    Drug: Nemolizumab

  • Hidradenitis patients receiving Interleukin (IL)-17 Inhibitors

    HS\_Interleukin (IL)-17 Inhibitors

    Drug: Anti-IL17

  • Hidradenitis patients receiving Tumor Necrosis Factor (TNF) Inhibitors

    HS\_Tumor Necrosis Factor (TNF) Inhibitors

    Drug: Anti-TNF

Interventions

  • DrugAnti-TNF

    Subject receives anti-TNF antibodies open-label as per guidelines

  • DrugAnti-IL12/23

    Drug page: Ustekinumab

    Subject receives anti-IL12/23 antibodies open-label as per guidelines

  • DrugAnti-IL17

    Subject receives anti-IL17 antibodies open-label as per guidelines

  • Subject receives Dupilumab open-label as per guidelines

  • DrugAnti-IL23

    Subject receives anti-IL23 antibodies open-label as per guidelines

  • Subject receives Baricitinib open-label as per guidelines

  • Subject receives Abrocitinib open-label as per guidelines

  • Subject receives Upadacitinib open-label as per guidelines

  • Subject receives Tralokinumab open-label as per guidelines

  • Subject receives Lebrikizumab open-label as per guidelines

  • Subject receives Nemolizumab open-label as per guidelines

06

What researchers measure

Primary outcomes

  1. Changes of molecular profiles over time

    Changes of immune cell composition, transcriptome, proteome and microbiome signatures

    Time frame: Baseline and week 2, week 4, week 12, week 52

  2. Changes of molecular profiles associated with disease severity/remission

    Changes of immune cell composition, transcriptome, proteome and microbiome signatures

    Time frame: Baseline and week 2, week 4, week 12, week 52

  3. Changes of molecular profiles associated with treatment

    Changes of immune cell composition, transcriptome, proteome and microbiome signatures

    Time frame: Baseline and week 2, week 4, week 12, week 52

  4. Changes of molecular profiles associated with treatment response

    Changes of immune cell composition, transcriptome, proteome and microbiome signatures

    Time frame: Baseline and week 2, week 4, week 12, week 52

Secondary outcomes

  1. Change in Eczema Area and Severity Index (EASI) score

    Clinical severity score

    Time frame: Baseline and week 1, week 2, week 12, week 52

  2. Change in Score of Atopic Dermatitis (SCORAD)

    Clinical severity score

    Time frame: Baseline and week 1, week 2, week 12, week 52

  3. Change in Psoriasis Area and Severity Index (PASI)

    Clinical severity score

    Time frame: Baseline and week 1, week 2, week 12, week 52

  4. Change in Hidradenitis Suppurativa Severity Score (IHS4)

    Clinical severity score

    Time frame: Baseline and week 1, week 2, week 12, week 52

07

Study locations

1 of 1 sites recruiting
  • Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel
    Kiel, 24105, Germany
    Recruiting
    • Stephan Weidinger, MD · Contact
    • Sascha Gerdes, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Dec 2028, 143 months after the start.

Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 143 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2017
First posted
Nov 30, 2017
StartActual
Jan 20, 2017
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03358693
Lead sponsor
Prof. Dr. Stephan Weidinger
Responsible party
Prof. Dr. Stephan Weidinger (Head, Inflammatory Skin Disease Center, University Hospital Schleswig-Holstein) — Sponsor-investigator
First posted
Nov 30, 2017
Start date
Jan 20, 2017
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 22, 2025

Study contacts

Stephan Weidinger, MD
Contact
sweidinger@dermatology.uni-kiel.de
004943150021101
Sascha Gerdes, MD
Contact
sgerdes@dermatology.uni-kiel.de
004943150021101
Stephan Weidinger, MD
principal investigator · Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion